首页> 外文期刊>Hepatology international >Model for End-Stage Liver Disease and liver cirrhosis-related complications
【24h】

Model for End-Stage Liver Disease and liver cirrhosis-related complications

机译:终末期肝病和肝硬化相关并发症的模型

获取原文
获取原文并翻译 | 示例
           

摘要

The Model for End-Stage Liver Disease (MELD) score has gained wide acceptance for predicting survival in patients undergoing liver transplantation. The strength of this score remains in the mathematical formula derived from a multivariate Cox regression analysis; it is a continuous scale and lacks a ceiling or a floor effect with a wide range of discrimination. It is based on objective, reproducible, and readily available laboratory data and the wide range of samples which have been validated. Liver cirrhosis complications such as ascites, encephalopathy, spontaneous bacterial peritonitis and variceal bleeding were not considered in the MELD score underestimating their direct association with the severity of liver disease. In this regard, several recent studies have shown that clinical manifestations secondary to portal hypertension are good prognostic markers in cirrhotic patients and may add additional useful prognostic information to the current MELD. We review the feasibility of MELD score as a prognostic predictor in patients with"liver cirrhosis-related complications.
机译:终末期肝病模型(MELD)评分已被广泛接受,用于预测接受肝移植的患者的存活率。该分数的强度保留在从多元Cox回归分析得出的数学公式中;它是一个连续的标尺,没有天花板或地板效果,且具有广泛的辨别力。它基于客观,可重复且易于获得的实验室数据以及经过验证的各种样品。 MELD评分未考虑肝硬化并发症,例如腹水,脑病,自发性细菌性腹膜炎和静脉曲张破裂出血,这低估了它们与肝病严重程度的直接关系。在这方面,最近的一些研究表明,肝硬化患者继发于门静脉高压的临床表现是良好的预后标志,并且可能为当前的MELD增加其他有用的预后信息。我们综述了MELD评分作为“肝硬化相关并发症”患者预后指标的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号